Revvity AlphaLISA SureFire Ultra Human Total EGF Receptor E746A-750 Deletion Detection Kit, 10,000 Assay Points

The Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase that binds EGF and related ligands to regulate cell proliferation, survival, differentiation, and migration. Upon ligand binding, EGFR undergoes dimerization and autophosphorylation, leading to activation of downstream signaling pathways including RAS/MAPK, PI3K/AKT, and PLCγ. EGFR plays a critical role in normal epithelial development and tissue homeostasis.

The E746_A750 deletion, one of the most prevalent EGFR exon 19 activating mutations, removes key amino acids within the kinase domain, destabilizing the inactive conformation of the receptor. This structural alteration results in ligand‑independent, constitutive EGFR activation and persistent downstream signaling that drives oncogenic transformation.

EGFR exon 19 deletions are particularly common in non‑small cell lung cancer (NSCLC) and are strongly associated with tumor growth, survival, and disease progression. These mutations represent well‑validated predictive biomarkers for response to EGFR‑targeted therapies. Small‑molecule tyrosine kinase inhibitors such as erlotinib, gefitinib, and osimertinib selectively inhibit mutant EGFR signaling and have become standard‑of‑care treatments for patients with EGFR exon 19‑deleted tumors, while monoclonal antibodies such as cetuximab and panitumumab are used in EGFR‑overexpressing cancers.

The AlphaLISA SureFire Ultra Human Total EGF Receptor E746A-750 Deletion Detection Kit is a sandwich immunoassay for the quantitative detection of total EGF receptor E746A-750 deletion in cellular lysates, using Alpha Technology.

Formats:

• The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
• The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
• The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
• The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

• Cell and tissue lysates
• Antibody modulators
• Biotherapeutic antibodies

AlphaLISA SureFire Ultra kits can be used for:

• Cellular kinase assays
• Receptor activation studies
• High-throughput screening for preclinical studies